{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T09:39:32Z","timestamp":1648978772723},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00108-019-00666-2","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T20:24:37Z","timestamp":1567196677000},"page":"1059-1073","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gro\u00dfgef\u00e4\u00dfvaskulitiden \u2013 Riesenzellarteriitis und Takayasu-Arteriitis"],"prefix":"10.1007","volume":"60","author":[{"given":"P. M.","family":"Villiger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"issue":"1","key":"666_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 revised international chapel hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"key":"666_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672","author":"B Hellmich","year":"2018","unstructured":"Hellmich\u00a0B, \u00c1gueda\u00a0AF, Monti\u00a0S et\u00a0al (2018) Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672","journal-title":"Ann Rheum Dis"},{"key":"666_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger\u00a0PM, Adler\u00a0S, Kuchen\u00a0S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927","journal-title":"Lancet"},{"issue":"4","key":"666_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et al (2017) Trial of Tocilizumab in giant-cell Arteritis. N\u00a0Engl J Med 377(4):317\u2013328","journal-title":"N Engl J Med"},{"key":"666_CR5","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr\u00a0AD, Jover\u00a0JA, Spiera\u00a0RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789\u20132797","journal-title":"Arthritis Rheum"},{"issue":"8","key":"666_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder\u00a0GG, Bloch\u00a0DA, Michel\u00a0BA et\u00a0al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122\u20131128","journal-title":"Arthritis Rheum"},{"key":"666_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00393-017-0331-3","volume":"76","author":"PM Villiger","year":"2017","unstructured":"Villiger\u00a0PM (2017) Gro\u00dfgef\u00e4\u00dfvaskulitiden. Z\u00a0Rheumatol 76:509\u2013523. \n                    https:\/\/doi.org\/10.1007\/s00393-017-0331-3","journal-title":"Z Rheumatol"},{"issue":"6\u20137","key":"666_CR8","doi-asserted-by":"publisher","first-page":"A544","DOI":"10.1016\/j.autrev.2012.01.003","volume":"11","author":"AT Borchers","year":"2012","unstructured":"Borchers\u00a0AT, Gershwin\u00a0ME (2012) Giant cell arteritis: a\u00a0review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 11(6\u20137):A544\u2013A554","journal-title":"Autoimmun Rev"},{"issue":"8","key":"666_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend\u00a0WP, Michel\u00a0BA, Bloch\u00a0DA et\u00a0al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129\u20131134","journal-title":"Arthritis Rheum"},{"key":"666_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco\u00a0C, Ramiro\u00a0S, Duftner\u00a0C et\u00a0al (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77:636\u2013643","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"666_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1759720X13512256","volume":"6","author":"WA Schmidt","year":"2014","unstructured":"Schmidt\u00a0WA (2014) Role of ultrasound in the understanding and management of vasculitis. Ther Adv Musculoskelet Dis 6(2):39\u201347","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"666_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.berh.2016.09.010","volume":"30","author":"F Muratore","year":"2016","unstructured":"Muratore\u00a0F, Pipitone\u00a0N, Salvarani\u00a0C, Schmidt\u00a0WA (2016) Imaging of vasculitis: state of the art. Best Pract Res Clin Rheumatol 30(4):688\u2013706","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"666_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/rheumatology\/keh513","volume":"44","author":"J Narvaez","year":"2005","unstructured":"Narvaez\u00a0J, Narvaez\u00a0JA, Nolla\u00a0JM et\u00a0al (2005) Giant cell arteritis and polymyalgia rheumatic: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. J\u00a0Rheumatol 44:479\u2013483","journal-title":"J Rheumatol"},{"issue":"3","key":"666_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1148\/radiol.14140056","volume":"273","author":"T Klink","year":"2014","unstructured":"Klink\u00a0T et al (2014) Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a\u00a0multicenter trial. Radiology 273(3):844\u2013852","journal-title":"Radiology"},{"key":"666_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1136\/annrheumdis-2013-204572","volume":"73","author":"S Prieto-Gonz\u00e1lez","year":"2014","unstructured":"Prieto-Gonz\u00e1lez\u00a0S, Depetris\u00a0M, Garc\u00eda-Mart\u00ednez\u00a0A et al (2014) Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a\u00a0prospective, case\u2013control study. Ann Rheum Dis 73:1388\u20131392","journal-title":"Ann Rheum Dis"},{"key":"666_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s00393-015-1674-2","volume":"75","author":"YH Lee","year":"2016","unstructured":"Lee\u00a0YH, Choi\u00a0SJ, Ji\u00a0JD, Song\u00a0GG (2016) Diagnostic accuracy of 18F-FDG PET or PET\/CT for large vessel vasculitis A meta-analysis. Z\u00a0Rheumatol 75:924\u2013931","journal-title":"Z Rheumatol"},{"key":"666_CR17","unstructured":"Hayreh SS. Anterior Ischemic Optic Neuropathy: Part II: a discussion for physicians. \n                    https:\/\/webeye.ophth.uiowa.edu\/eyeforum\/article\/AION\/AION-part2.htm"},{"issue":"5","key":"666_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/ard.2007.086330","volume":"67","author":"C Salvarani","year":"2008","unstructured":"Salvarani\u00a0C, Pipitone\u00a0N, Boiardi\u00a0L, Hunder\u00a0GG (2008) Do we need treatment with tumour necrosis factor blockers for giant cell arteritis? Ann Rheum Dis 67(5):577\u2013579","journal-title":"Ann Rheum Dis"},{"key":"666_CR19","first-page":"w13156","volume":"141","author":"M Seitz","year":"2011","unstructured":"Seitz\u00a0M, Reichenbach\u00a0S, Bonel\u00a0HM et al (2011) Rapid induction of remission in large vessel vasculitis by IL\u20116 blockade. A case series. Swiss Med Wkly 141:w13156","journal-title":"Swiss Med Wkly"},{"key":"666_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez091","author":"S Adler","year":"2019","unstructured":"Adler\u00a0S, Reichenbach\u00a0S, Gloor\u00a0A et\u00a0al (2019) Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxf). \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kez091\n                    \n                   (Mar 26. pii: kez091. doi:)","journal-title":"Rheumatology (Oxf.)"},{"key":"666_CR21","volume-title":"Long-term outcome of tocilizumab for patients with giant cell arteritis: results from part 2 or the GIACTA trials","author":"JH Stone","year":"2019","unstructured":"Stone\u00a0JH et al (2019) Long-term outcome of tocilizumab for patients with giant cell arteritis: results from part 2 or the GIACTA trials. EULAR Annual Meeting; OP0140"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-00666-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:01:14Z","timestamp":1598659274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-00666-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-00666-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"30 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>P.M.\u00a0Villiger<\/b>: Finanzielle Interessen: Honorar f\u00fcr Referat: Roche, Sanofi. Advisory Board: Roche, Sanofi. Nichtfinanzielle Interessen: Ordinarius f\u00fcr Rheumatologie und klinische Immunologie, Medizinische Fakult\u00e4t, Universit\u00e4t Bern, Schweiz | Direktor und Chefarzt, Departement f\u00fcr Rheumatologie, Immunologie und Allergologie, Universit\u00e4tsspital (Inselspital) Bern, Schweiz.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}